P2D Bioscience receives $2.3 million in NIH funding
P2D Bioscience, a Blue Ash-based speciality pharmaceutical company, has been awarded four grants totaling $2.3 million from the National Institutes of Health (NIH) in the past two months.
According to Dr. Frank Zemlan, founder and CEO of P2D Bioscience, the grants include the development of a new comprehensive test for the diagnosis of genetic liver diseases, new drugs for the treatment of acute leukemia and Alzheimer's disease, and a new drug to improve stem cell transplant therapy for treating leukemia and lymphomas.
"We've received several grants from the NIH in the past, but the scope of the recent grants will help us continue to develop medical advances that improve the lives and health of people who are afflicted with these diseases," Dr. Zemlan stated.
Founded in 2005, P2D Bioscience focuses on rapid product development aimed at reducing risks, timelines and the cost of drug development. The company currently has three proprietary products in clinical and preclinical development primarily for orphan diseases. They include a treatment for Prader-Willi Syndrome, a disorder that results in morbid obesity, drugs to treat Frontotemporal Dementia, and a drug to improve the symptoms of Attention Deficit Hyperactivity Disorder.
In addition to its office and labs in Blue Ash, the company has a satellite office in Mumbai, India.
Click here to learn more about P2D Bioscience.
Newsletter Issue: Spring 2014